Literature DB >> 27197733

Response to Wise et al. (Tiotropium safety in real life populations).

Sven Schmiedl1,2, Petra Thürmann1,2, Rainald Fischer3, Dominik Rottenkolber4,5, Marietta Rottenkolber6,7.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27197733      PMCID： PMC4972174          DOI： 10.1111/bcp.12970

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  Tiotropium Respimat inhaler and the risk of death in COPD.

Authors:  Robert A Wise; Antonio Anzueto; Daniel Cotton; Ronald Dahl; Theresa Devins; Bernd Disse; Daniel Dusser; Elizabeth Joseph; Sabine Kattenbeck; Michael Koenen-Bergmann; Gordon Pledger; Peter Calverley
Journal:  N Engl J Med       Date:  2013-08-30       Impact factor: 91.245

2.  Tiotropium and the risk of death in COPD.

Authors:  Katia M C Verhamme; Nico van Blijderveen; Miriam C J M Sturkenboom
Journal:  N Engl J Med       Date:  2014-01-30       Impact factor: 91.245

3.  Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.

Authors:  Katia M C Verhamme; Ana Afonso; Silvana Romio; Bruno C Stricker; Guy G O Brusselle; Miriam C J M Sturkenboom
Journal:  Eur Respir J       Date:  2013-03-21       Impact factor: 16.671

4.  Risk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic review.

Authors:  Yoon K Loke; Sonal Singh
Journal:  Ther Adv Drug Saf       Date:  2013-02

5.  Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.

Authors:  Yaa-Hui Dong; Chia-Hsuin Chang; Joshua J Gagne; Chia-Lin Hsu; Mei-Shu Lai
Journal:  Pharmacotherapy       Date:  2016-01       Impact factor: 4.705

6.  Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.

Authors:  Sven Schmiedl; Rainald Fischer; Luisa Ibanez; Joan Fortuny; Petra Thürmann; Elena Ballarin; Pili Ferrer; Monica Sabaté; Dominik Rottenkolber; Roman Gerlach; Martin Tauscher; Robert Reynolds; Joerg Hasford; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2015-12-23       Impact factor: 4.335

Review 7.  Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; David Price; Klaus F Rabe; Hendrik Schmidt; Norbert Metzdorf; Bartolome Celli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-16

8.  Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.

Authors:  Donald P Tashkin; Inge Leimer; Norbert Metzdorf; Marc Decramer
Journal:  Respir Res       Date:  2015-06-02

9.  Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.

Authors:  Robert Wise; Peter M A Calverley; Ronald Dahl; Daniel Dusser; Norbert Metzdorf; Achim Müller; Andy Fowler; Antonio Anzueto
Journal:  NPJ Prim Care Respir Med       Date:  2015-11-05       Impact factor: 2.871

10.  Tiotropium safety in 'real-world' populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology.

Authors:  Robert Wise; Antonio Anzueto; Ronald Dahl; Daniel Dusser; Peter Calverley
Journal:  Br J Clin Pharmacol       Date:  2016-05-19       Impact factor: 4.335
View more
  1 in total

1.  Response to Wise et al. (Tiotropium safety in real life populations).

Authors:  Sven Schmiedl; Petra Thürmann; Rainald Fischer; Dominik Rottenkolber; Marietta Rottenkolber
Journal:  Br J Clin Pharmacol       Date:  2016-05-20       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.